李娟+尚彦彦+席红利

[摘要] 目的 评价血清CA125（糖链抗原125）、CA199（糖链抗原199）、CA153（糖链抗原153）联合检测对肺癌诊断及分期的临床价值。 方法 在2015年6月～2016年6月期间选取60例健康体检者、60例良性肺病患者、60例疑似肺癌患者為此次研究对象，对本次受检者进行CA199、CA125、CA153、CEA指标检测，再分析肿瘤标志物在判断患者病情、预后的重要性。 结果 肺癌患者CA199（135.48±25.36）U/mL、CA125（95.45±15.48）U/mL、CA153（21.45±3.69）U/mL、CEA（45.58±5.42）μg/mL均高于良性肺病组、健康体检组受检者，差异有统计学意义（P<0.05）。同时从诊断价值性角度分析，仅联合诊断特异性90.00%、敏感性98.00%、误诊率10.00%、漏诊率2.00%与病理检查结果无统计学意义（P>0.05）；从TNM分期角度分析，肺癌患者Ⅳ期和Ⅲb期的CA199、CA125、CA153水平值明显高于Ⅲa期、Ⅱ期和Ⅰ期，差异有统计学意义（P<0.05）。 结论 血清CA125、CA199、CA153联合检测在肺癌诊断、临床分期中价值显著。

[关键词] CA125；CA199；CA153；肺癌；分期

[中图分类号] R734.2 [文献标识码] A [文章编号] 2095-0616（2017）13-101-03

[Abstract] Objective To evaluate clinical value of combined detection of serum CA125 （carbohydrate antigen 125），CA199 （carbohydrate antigen 199） and CA153 （carbohydrate antigen 153） in diagnosis and Staging of lung cancer. Methods 60 healthy cases，60 patients with benign lung disease and 60 suspected lung cancer from June 2015 to June 2016 were selected as research objects.All subjects in this research were given detection of CA199，CA125，CA153 and CEA.Significance of tumor marker in judging disease and prognosis of patients was analyzed. Results CA199，CA125，CA153 and CEA of patient with lung cancer were respectively （135.48±25.36）U/mL，（95.45±15.48）U/mL， （21.45±3.69）U/mL and （45.58±5.42）ug/mL，all higher than those of the benign lung disease group and subjects in the healthy cases group （P<0.05）.By analyzing from the perceptive of diagnostic value，specificity 90.00%，sensitivity 98.00%，misdiagnosis rate 10.00% and omission diagnostic rate 2.00% of only combined detection had no difference with pathological examination results （P>0.05）.By analyzing from the perceptive of TNM staging，values of CA199，CA125 and CA153 levels patients with lung cancer in Ⅳ stage and Ⅲb stage，significantly higher than those in Ⅲa stage，Ⅱ stage and I stage （P<0.05）. Conclusion Combined detection of serum CA125，CA199 and CA153 in diagnosis and clinical staging of lung cancer has significant value.

[Key words] CA125；CA199；CA153；Lung cancer；Staging

肺癌具有死亡率高、发病率高、病情重特点，其发病原因与生活方式、环境因素、吸烟史有关[1]。目前临床上对于肺癌患者常用治疗方案为化疗、手术、放疗，其虽然可延长患者生存时间，但缺乏针对性，而此时加强患者临床检测，能够对病情进展、预后起到检测作用，从而确保治疗方案的针对性[2]。随着实验室检查的广泛应用，对于肺癌患者临床常用肿瘤标志物检查，其具有重复性强、操作简单、准确率高等特点，不仅能够分辨肿瘤分期，还可对患者病情预后具有一定应用价值性[3]。本文旨在探讨血清CA125、CA199、CA153联合检测对肺癌患者的临床意义，现报道如下。

1 资料与方法

1.1 一般资料

选择60例疑似肺癌患者、60例良性肺病患者、60例健康体检者为此次研究对象，受检者均在2015年6月～2016年6月期间收治，本次受检者未经实验室检查和病理检查确诊。排除依从性低受检者；排除沟通障碍受检者；……